Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

Core Insights - Aptose Biosciences Inc. has received an additional US$2.0 million from Hanmi Pharmaceutical as part of an US$8.5 million loan facility agreement, bringing the total received to US$4.5 million [1] - The company is developing tuspetinib (TUS) as a frontline therapy for newly diagnosed acute myeloid leukemia (AML), demonstrating promising antileukemic activity and safety across diverse patient populations [2] - Tuspetinib is a once-daily oral agent that inhibits multiple kinases associated with AML, maintaining a favorable safety profile compared to other treatments [2] - The ongoing TUSCANY Phase 1/2 study is evaluating TUS in combination with azacitidine and venetoclax for patients ineligible for induction chemotherapy [2] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's pipeline includes small molecule cancer therapeutics aimed at providing efficacy without overlapping toxicities [3] - Tuspetinib is the lead compound, showing activity as both a monotherapy and in combination therapy for relapsed or refractory AML, and is being developed for newly diagnosed patients [3]